• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Oncology: International Journal of Cancer Research and Treatment >Concurrent Chemoradiotherapy with Low-Dose Cisplatin plus 5-Fluorouracil for the Treatment of Patients with Unresectable Head and Neck Cancer.
【24h】

Concurrent Chemoradiotherapy with Low-Dose Cisplatin plus 5-Fluorouracil for the Treatment of Patients with Unresectable Head and Neck Cancer.

机译：低剂量顺铂加5-氟尿嘧啶的同时放化疗治疗无法切除的头颈癌患者。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Objective: The purpose of this study was to determine the efficacy of concurrent chemoradiotherapy using conventional radiotherapy combined with low-dose daily 5-fluorouracil (5FU) and cisplatin (CDDP) for the locally unresectable head and neck cancer patients. Patients and Methods: From September 1996 through December 2000, we carried out a phase II study of concurrent chemoradiotherapy with low-dose CDDP plus 5FU for the treatment of patients with unresectable squamous cell carcinoma of the head and neck. Chemoradiotherapy consisted of irradiation with 1.6-2.0 Gy/day for 5 days per week up to a total dose 68 Gy and CDDP 3 mg/m(2) by intravenous infusion over 1 h plus 5FU 150 mg/m(2) by intravenous infusion over 24 h per day for 5 days per week. Results: Ninety percent of the patients had stage IV disease, including 65% of patients with T4 disease. Thirty-three patients (83%) received the full treatment as planned; 39 (98%) received full-dose radiotherapy and 33 (83%) full-dose chemotherapy. Of the 40 patients evaluable for response, 20 (50%) achieved complete response (CR) and 12 (30%) partial response with an overall response rate of 80%. Among the 20 CR patients, 15 underwent endoscopic blind biopsies and 4 had positive lesions. The most frequently observed toxicity was mucositis. Ten patients developed grade III mucositis, and 3 patients required enteral nutritional support through a feeding tube. Grade III leukopenia, anemia and thrombocytopenia were observed in 28, 25 and 20% of the patients, respectively. The median duration of follow-up at the time of analysis was 18 months. The median survival time was 23 months. The responders survived longer (34 months) than the nonresponders (4 months; p < 0.05). Conclusion: This regimen is safe and efficacious in the treatment of patients with advanced unresectable head and neck cancer. Copyright 2002 S. Karger AG, Basel
机译：目的：本研究的目的是确定常规放疗联合低剂量每日5-氟尿嘧啶（5FU）和顺铂（CDDP）联合放化疗对局部无法切除的头颈癌患者的疗效。患者与方法：从1996年9月至2000年12月，我们进行了低剂量CDDP加5FU同步放化疗的II期研究，该疗法用于治疗无法切除的头颈部鳞状细胞癌。化学放疗包括每周1天以1.6-2.0 Gy /天的辐照量连续5天，直至总剂量为68 Gy，CDDP 3 mg / m（2）静脉滴注1小时，再加上5FU 150 mg / m（2）每天超过24小时，每周5天。结果：90％的患者患有IV期疾病，包括65％的T4疾病患者。 33名患者（83％）按计划接受了全面治疗; 39（98％）人接受了全剂量放疗，而33（83％）人接受了全剂量化疗。在40位可评估缓解的患者中，有20位（50％）达到完全缓解（CR）和12位（30％）部分缓解，总缓解率为80％。在20例CR患者中，有15例接受了内镜盲活检，其中4例为阳性。最常见的毒性反应是粘膜炎。十名患者发展为III级粘膜炎，三名患者需要通过饲管进行肠内营养支持。分别在28％，25％和20％的患者中观察到III级白细胞减少，贫血和血小板减少。分析时的中位随访时间为18个月。中位生存时间为23个月。反应者（34个月）比未反应者（4个月; p <0.05）生存时间更长。结论：该方案治疗晚期无法切除的头颈癌是安全有效的。版权所有2002 S. Karger AG，巴塞尔

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号